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Abstract
Random allocation models used in clinical trials aid researchers in determining which of a particular treatment provides
the best results by reducing bias between groups. Often however, this determination leaves researchers battling ethical
issues of providing patients with unfavorable treatments. Many methods such as Play the Winner and Randomized Play
the Winner Rule have historically been utilized to determine patient allocation, however, these methods are prone to
the increased assignment of unfavorable treatments. Recently a new Bayesian Method using Decreasingly Informative
Priors has been proposed by1, and later2. Yet this method can be time consuming if MCMC methods are required. We
propose the use of a new method which uses Dynamic Linear Model (DLM)3 to to increase allocation speed while also
decreasing patient allocation samples necessary to identify the more favorable treatment. Furthermore, a sensitivity
analysis is conducted on multiple parameters. Finally, a Bayes Factor is calculated to determine the proportion of
unused patient budget remaining at a specified cut off and this will be used to determine decisive evidence in favor of
the better treatment.
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Introduction
Clinical trials are controlled methods by which researchers
may “obtain sound scientific evidence for supporting the
adoption of new therapies in clinical medicine”4. Clinical
trials are defined by4 “to consist of at least two groups
of patients who are as similar as possible except for the
administered treatment whereby the groups are decided
through randomization”. Extensive research has be done
in the randomization of clinical trials. The most common
approach consists of equally allocating the same number
of subjects to two treatments. Yet,5 pointed out this
method suffers from ethical issues provided one drug
is superior, while also possessing a less than adequate
parameter estimating ability. Thus one would like to be
able to sequentially allocate participants in such a way that
the randomization remains preserved, while also skewing
participants to the better treatment. This is known as adaptive
allocation.
Methods for adaptively allocating subjects between
treatments include the earliest works conducted by6 who
was the first to look at what has become known as the
adaptive design. Additional adaptive design works include
those of7, as well as8. Likewise,9 contribution to adaptive
allocation led to the Play the Winner Rule which allocates
patients to future successful trials based on the success
of one trial or failure of the other (see4 for details).
While10 suggests this method can be a useful substitute
for equal allocation, he indicates there is lower power
when compared to equal allocation models. The Play the
Winner Rule was modified by11 into the Randomized Play
the Winner Rule. Further works include those of5 as well
as12.13 examined a comparison between the optimal design
of14 and the approach of15 for binary outcomes using a
Bayesian approach. Likewise,1 used a Bayesian approach
to create what he termed “Decreasingly Informative Prior”
information to examine how adaptive allocation performed
on binary variables. Each of these aforementioned methods
are a type of urn randomization method and as such, each of
these methods have binary responses leading to proportional
allocation. For more on urn randomization methods and their
properties see16.
Another method used is the Bayesian Adaptive Design in
which assignment of either treatment or control is conducted
through adaptive allocation. Extensive work has been done
in this area including the works of17 who determined
the method provided “improved patient outcomes and
increased power” along with a “lower expected sample
size” in a three arm trial in which one treatment was
actually better than the others. Another area this method
has been used is in the Recurrent Glioblastoma trial
conducted by18. They concluded “the use of Bayesian
adaptive designs in glioblastoma trials would result in trials
requiring substantially fewer overall patients, with more
patients being randomly assigned to efficacious arms”. The
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lung cancer study of19 utilized a probit model and was
found, along with a suitable early stopping rule, to be an
ethical design which can be used to improve personalized
medicine. Bayesian adaptive design has been used to design
a trial to analyze acute heart failure syndromes by20.
They determined this type of “clinical trial represents
an innovative and potentially paradigm-shifting method of
studying personalized treatment options for AHFS”.
Regardless of the previously mentioned designs chosen,
the y patients enter a random allocation study sequentially at
different times. Thus patients entering a random allocation
study may be considered a set of time series measurements.
Furthermore, throughout the trial there will be a total of N
patients. Let T be the index set for patient yt measured in
a total of N patients. Because these yt patients enter the
allocation study sequentially, more information regarding
allocation to the better treatment is known at, say, patient y10,
than at patient y9. This allows the researchers to learn more
information about treatment effectiveness as patients enter
the study. However, with the Bayesian allocation designs,
this information becomes a Bayesian Learning Design; as
the information is updated, the Bayesian design learns which
treatment is better.
Bayesian adaptive designs use Bayesian updating methods
to allocate subjects to treatments. The ability of using the
posterior as the prior through repeated updating makes
these Bayesian methods “a natural framework for making
decisions based on accumulating data during a clinical
trial”15. Furthermore, this updating ability provides as a
fortuitous side effect, according to21 “the ability to quantify
what is going to happen in a trial from any point on
(including from the beginning), given the currently available
data”.
Bayesian Methods
The basic premise surrounding Bayesian methods is known
as Bayes rule, named after Rev. Thomas Bayes who
postulated the probability of some unknown parameter θ,
given the corresponding observations y, was simply the ratio
of the probability of the joint density function p(θ, y) to the
probability we observe the value y. Mathematically speaking
this is
p(θ|y) = p(θ)p(y|θ)/p(y) (1)
where p(θ|y) is now the posterior, or updated distribution for
θ given some y and
p(θ)p(y|θ) = p(θ, y) (2)
According to22 p(θ) is some prior distribution of
parameters and p(y|θ) is the sampling distribution such that
conditioning on the known y data will lead to the posterior
distribution (See22 for more details.) This idea has been
extended upon by23 for time series data. The learning ability
available through this updating process in these Bayesian
methods has been extended by3 using Dynamic Linear
Models (DLM). The DLM uses this Bayesian Learning
Process to update and forecast the y observations such that
Yt = F
′
tθt + νt (3)
θt = Gtθt−t + ωt
where
νt ∼ N(0, Vt) (4)
ωt ∼ N(0,Wt)
Here, θt represent the forecast parameter Ft where Ft
is a known n× r matrix of independent variables, Gt is a
known n× n system matrix,Wt is a known n× n evolution
variance matrix, and Vt is a known r × r observational
variance matrix.
The prior forecast parameter θt is found by noting
(θt−1|Dt−1) ∼ N(mt−1, Ct−1) for some mean mt−1
and variance matrix Ct−1. The prior for θt may be seen to
be (θt|Dt−1) ∼ N(at, Rt) whereby at = Gtmt−1 with
Rt = GtCt−1G
′
t +Wt. The one step ahead forecast is
calculated as (Yt|Dt−1) ∼ N(ft, Qt). Here, ft is the current
treatment allocation for patient y, while Qt is the forecast
allocation variance for patient y. The posterior for θt relies
on (θt−1|Dt−1) ∼ N(mt, Ct)
Furthermore, mt = mt−1 +Atet, where mt repre-
sents the current mean matrix, Ct = Rt −AtQtA′t where
Ct is the current variance matrix, At = RtFtQ−1t where
At is the adaptive coefficient, and et = Yt − ft represents
the error term.
Random Allocation Methods
Random Allocation models of24 proposed the solution to
minimizing the responses by using
wA =

QAt
√
fBt
QAt
√
fBt+QBt
√
fAt
if (fAt < fBt |
QAt
√
fBt
QBt
√
fAt
> 1)
QAt
√
fBt
QAt
√
fBt+QBt
√
fAt
if (fAt > fBt |
QAt
√
fBt
QBt
√
fAt
< 1)
1
2 Otherwise
(5)
wB = 1− wA
as an optimal method to obtain weighted allocation values.
However,25 demonstrated the design of24 was slightly flawed
for negative values involving at least one of either fAt or fBt .
The optimal design solution posed by25 was shown to be
wA =
QAt
√
γBt
QAt
√
γBt +QBt
√
γAt
(6)
wB = 1− wA
where γA = Φ
 fAt − fBt√
Q2At +Q
2
Bt
 ,
γB = Φ
 fBt − fAt√
Q2At +Q
2
Bt

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Recently,2 examined how a Decreasingly Informative Prior
distribution impacted the allocation using each of these
equations. The current work uses the DLM to randomly
allocate patients to examine these impacts. Yet because the
DLM is an updating method at each value, the values for each
of fAt , fBt , QAt , QBt will change at each iteration, leading
to different weight values based on the starting values.
Algorithm
To generate the allocation values
1. Initiate the DLM by selecting initial values for µA, µB ,
ωt, CtA , CtB , QtA , QtB .
2. Calculate predicted values and variances fAt (Ft =
[1, 0]), fBt (Ft = [1, 1]), QAt and QBt
3. Compute wA and wB
4. Sample a Uniform(0,1) random variable U and
compare wA
5. If wA < U , allocate to Treatment A (Ft = [1, 0]),
otherwise allocate to treatment B (Ft = [1, 1])
6. Conduct experiment and observe yt
7. Update the DLM and return to step 2
Simulation Study
Seven scenarios were examined in2 and these values may be
observed in Table 1. Simulation sizes of 1,000 and 10,000
were considered and run for several scenarios however the
results were almost identical, therefore, in order to avoid
any unnecessary computation time the DLM was used to
randomly allocate each scenario through 1000 simulations.
As in2 treatment allocation probabilities, total number of
allocations in each treatment group, and total number of
successes was recorded, however, the current authors have
only included the treatment allocation associated with the
preferred treatment and these may be seen in Table 2.
Although2 utilized Bayesian updating to obtain the values
of the decreasingly Informative Prior, each iteration was
manually done, leading to a large completion time due to
the extensive number of necessary simulation calculation
runs. In the current method using the DLM, these times
were greatly reduced. Each scenario was run using R Studio
version 1.2.1335 on an ACER computer with an AMD Ryzen
5 2500U with Radeon Vega Mobile Gfx 2.00 GHz processor
and 8.00 GB of RAM using Windows 10. Additionally,
each run took approximately 45 seconds to complete, with
the longest run time 164 seconds corresponding to the
budget size N = 200, while the shortest run time 23 seconds
corresponding to a budget size N = 34.
Table 1. Simulation Scenarios
Scenario Differences Standard Planned Sample
Deviation Budget
1 0 20 128
2 10 15 74
3 10 20 128
4 10 25 200
5 20 20 34
6 20 25 52
7 20 30 74
The results for a mean difference of 0 and standard
deviation of 20 may be seen in Table 2 and a plot of both
equal and unequal allocation may be observed in Figure 1
below. The mean number of allocations was obtained using
each method. Notice the mean allocation using the method
of24 was 63.538, which is as expected, given the probability
of allocation to Treatment A was 0.5. One may observe this
outcome in Figure 1a where no allocation differences exist .
Table 2. Treatment Group Mean Sample Size. Italicized values
indicate Treatment B was selected
Mean Standard Sample Equation 5 Equation 6
Difference Deviation Budget Allocation Allocation
0 20 128 63.538 32.745
10 15 74 36.470 4.928
10 20 128 63.146 13.283
10 25 200 99.883 34.589
20 20 34 16.673 2.390
20 25 52 25.641 2.793
20 30 74 36.958 3.859
When the DLM was applied to the unequal method of25,
the mean number applied to Treatment A is 95.255, while the
mean number allocated to Treatment B is 32.745. Under the
methods of25,24, and2, the smaller value was taken to be the
better allocation, therefore, it appears as though Treatment B
is the favorable treatment.
Figure 1 Here titled AllocationFirstFormulaNoCovariate
a). Equal Allocation b). Unequal Allocation
Figure 1. Comparison Between Equal and Unequal Allocation
An examination of Figure 1b illustrates the allocation
probabilities for both Treatment A and Treatment B.
Each allocation begins at 0.5, however, dependent upon
the particular treatment which was allocated, the weights
either increase or decrease. The mean allocation weight for
treatment A was 0.749, while the mean weight for Treatment
B was 0.251. The weighted values for Treatment A are seen
in Figure 1b as the red line, while those for Treatment B
are noticeably the opposite. This is due to the symmetry
between the two weighting schemes. Problematic to these
two methods was the fact that with equal variance, the
treatment allocation weights remained at approximately 0.5
in the method of24, while using the method proposed by25,
the treatment allocation proportions immediately converged.
However, determining behavior of the treatment allocation
weights upon varying the parameter values associated with
the mean, system variance and observational variance values
is important in determining model behavior. By analyzing
model behavior through these parameter modifications
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clinical trial researchers can determine the minimum number
of subjects necessary to detect the favorable treatment,
enabling them to conclude the study earlier, thereby avoiding
the ethical issues presented by the continuation of providing
unfavorable treatments.
Therefore, the current authors chose a budget size of 100
and a sensitivity analysis was conducted using various values
for µB , ωt, and ctB , while keeping Qt = 1. The values
chosen for µB were 1 - 5, leading to HA : µB = 1 through
HA : µB = 5. This lead to the hypothesis
H0 : µB = 0
HA : µB 6= 0 (7)
whereby µB = 1, 2, 3, 4, 5 By keeping Qt = 1, and using
the patient budge size of 100, the values chosen for µB
represented a 1% to a 5% difference in the two treatments.
The values for ωt were chosen as 0.1, 0.01, and 0.001,
which represent decreased variability between times, thereby
increasing certainty of between time variability impact.
Finally, the values for ctB were chosen to be 0.1, 0.001,
and 0.000001. These values were chosen to represent an
increased knowledge group B has no effect. Some of these
weighted allocation proportion values may be observed in
Figure 2. It must be noted these were not all the weighted
allocation proportion values, and these represent each of the
µB values chosen, and each of the ωt values chosen, but only
the ctB = 0.000001 to illustrate the impact. Using a mean
µB = 1 with ωt = 0.1 the mean proportion of allocation
values to treatment A was 0.607, while the mean proportion
allocated to treatment B was 0.393, which may be observed
in Figure 2a. Furthermore, the mean number at which the
treatment allocation switched from B to A was 39.749.
Compare this to the treatment proportions when ωt = 0.01 in
Figure 2b. Here, the mean proportion of allocation values to
treatment A was 0.595, while the mean proportion allocated
to treatment B was 0.405. Likewise, the mean number
at which the treatment allocation switched from B to A
was 41.281. Finally, letting ωt = 0.001 one may observe
in Figure 2c the mean proportion of allocation values to
treatment A was 0.538, while the mean proportion allocated
to treatment B was 0.462, with the mean number at which
the treatment allocation switched from B to A was 46.730.
Next the mean was increased to 3, µB = 3 and the analysis
was conducted. When using ωt = 0.1 the mean proportion of
allocation values to treatment A was 0.796, while the mean
proportion allocated to treatment B was 0.204, which may
be observed in Figure 2g. Interestingly, the mean number
at which the treatment allocation switched from B to A
decreased from 37.749 using µB = 1 to 18.156 using µB =
3. When ωt = 0.01 one may see in Figure 2h the mean
proportion of allocation values to treatment A was 0.753,
while the mean proportion allocated to treatment B was
0.247. This led to a the mean number necessary to switch
from treatment B to treatment A to decrease from 41.281 at
µB = 1 to 24.450 using µB = 3. Lastly, when ωt = 0.001
the mean proportion of allocation values to treatment A was
0.610, while the mean proportion allocated to treatment B
was 0.390, which may be observed in Figure 2i. Once again
the mean number at which the treatment allocation switched
from B to A decreased from 46.730 using µB = 1 to 39.185
using µB = 3, however, this value is slightly higher than
when using ωt = 0.01.
Finally, the output was analyzed when µB = 5. When
using ωt = 0.1 the mean proportion of allocation values to
treatment A was 0.892, while the mean proportion allocated
to treatment B was 0.108, which may be observed in
Figure 2m. The mean number at which treatment allocation
went from B to A was 8.052, which is much lower that the
mean values for ωt = 0.1 when using µB = 1 or 3. When
ωt was decreased to 0.01, the mean proportion of allocation
values to treatment A was 0.832, while the mean proportion
allocated to treatment B was 0.168, which may be observed
in Figure 2n. When using ωt = 0.01, the mean number at
which treatment allocation switched from A to B increased
from 8.052 to 15.209, which represents approximately twice
the needed patient budget. Lastly, when the value for ωt
was decreased to 0.001 the mean proportion of allocation
values to treatment A was 0.669, while the mean proportion
allocated to treatment B was 0.331, which may be observed
in Figure 2o. However, here the mean number at which
treatment allocation switched from B to A increased from
15.209 to 33.538. This represents not only more than double
the patient budget needed when going from ωt = 0.01 to
ωt = 0.001, but a 4 times increase when going from ωt =
0.1 to ωt = 0.001
It appears clear that as the mean value for treatment B
µB increases, the mean allocation probabilities also increase
to higher convergent values. Likewise, the mean number of
allocations necessary to switch from treatment B to treatment
A decreases as µB increases. Yet this impact is counteracted
by increasing the certainty around ωt. Thus increasing time
variability between times ti−1 and ti, indicates a larger
necessary patient budget required to detect switching from
treatment B to treatment A.
Figure 2 Here titled compweightA
Stopping Rule
In an effort to keep this model fully Bayesian, a power
analysis was conducted using a Bayes Factor, and the 95%
credible intervals along with the medians were calculated.
Determination of an appropriate Bayes Factor value has been
described in26, who indicate a Bayes Factor greater than 100
indicates Decisive evidence against the null hypothesis of no
difference.
However,27 use the opposite notation for the Bayes Factor,
whereby the null hypothesis is in the numerator yielding
p(H0 | (D)) = P (D | H0)P (H0))
P (D | H0)p(H0) + P (D | H1)p(H1) (8)
whereby they have the null hypothesis in the numerator and
this leads to the Bayes Factor
BF01 =
P (D | H0)
P (D | H1) (9)
which leads to their suggestion that a Bayes Factor
less than 1100 provides decisive evidence against the null
hypothesis and in favor of the alternative hypothesis. The
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(a) µB = 1, ωt = 0.1 (b) µB = 1, ωt = 0.01 (c) µB = 1, ωt = 0.001
(d) µB = 2, ωt = 0.1 (e) µB = 2, ωt = 0.01 (f) µB = 2, ωt = 0.001
(g) µB = 3, ωt = 0.1 (h) µB = 3, ωt = 0.01 (i) µB = 3, ωt = 0.001
(j) µB = 4, ωt = 0.1 (k) µB = 4, ωt = 0.01 (l) µB = 4, ωt = 0.001
(m) µB = 5, ωt = 0.1 (n) µB = 5, ωt = 0.01 (o) µB = 5, ωt = 0.001
Figure 2. Comparison of Weight Allocation proportions for ωt = 0.1, 0.01 and 0.001 and µB = 1, 2, 3, 4, 5 and CtB = 0.000001
with bars representing the uncertainty across simulations.
Bayes Factor was calculated using the Bayesian Two Sample
T-Test discussed in27. They define the Bayes Two Sample T
Test as
BF01 =
Tν(t | 0, 1)
Tν(t | n
1
2
δ λ, 1 + nδσ
2
δ )
(10)
The notation of27 was chosen as the more appropriate
notation, and a stopping criterion was chosen to be a Bayes
Factor of 1100 , to provide “decisive evidence” and support
towards the effective treatment. Any significant Bayes factor
indicated a 100 times more likely chance the allocation had
switched. Likewise, any indecisive Bayes Factor indicated
the switch to the better treatment had not occurred. The
bold numbers represent the Bayes Factor calculated at the
budget size N = 100 The values in parenthesis in Table 3
and Table 4 represent the median and 95% credible interval
values required to switch treatments.
Using µB = 1 and ωt = 0.1 and ctB = 0.000001 it can
be seen the median switch occurs at 52 (95% credible
interval 29, 88) with a decisive Bayes Factor value 0.009,
indicating this was 100 times more likely to have switched
to the favorable treatment. However, when ωt = 0.01 the
median switch occurs at 90 (95% credible interval 61, 100)
Table 3. Non Covariate Budget Allocation N using µB = 1, 2, 3
(Q0.025, Q0.5, Q0.975) P(N ≥ 100). Italicized values indicate
Noteworthy Bayes Factor
µB
Ct ωt 1 2 3
0.1
0.1 (30, 52, 91), 0.007 (28, 39, 59), 0.000 (28, 37, 56), 0.001
0.01 (60, 89, 100), 0.319 (64, 80, 100), 0.061 (58, 72, 97.025), 0.018
0.001 (100, 100, 100),1.000 (100, 100, 100),0.985 (75.975, 89.5, 100),0.158
0.001
0.1 (30, 51, 88), 0.007 (26, 45, 83), 0.005 (27, 36, 57), 0.001
0.01 (61, 89, 100), 0.303 (64.975, 80, 100), 0.670 (58, 72, 94), 0.011
0.001 (100, 100, 100),1.000 (100, 100, 100),1.000 (98, 100, 100),0.949
0.000001
0.1 (29, 52, 88), 0.009 (28, 40, 60), 0.000 (28, 37, 54), 0.002
0.01 (61, 90, 100), 0.327 (65, 80, 100), 0.071 (59, 72, 95.025), 0.014
0.001 (100, 100, 100),1.000 (100, 100, 100),1.000 (99, 100, 100),0.973
with a indecisive Bayes Factor 0.327, indicating at N = 100
the switch to the favorable treatment had not yet occurred.
Finally, when ωt = 0.001, all quantiles were 100, with an
indecisive Bayes Factor = 1.000 thereby indicating the more
effective treatment had not yet been detected atN = 100 and
no switching had occurred.
Using µB = 3 and ωt = 0.1 and ctB = 0.000001 median
switch occurs at 37 (95% credible interval 28, 54) with a
decisive Bayes Factor 0.002, indicating this was 100 times
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Table 4. Budget Allocation N using µB = 4, 5 (Q0.025, Q0.5,
Q0.975) P(N ≥ 100). Italicized values indicate Noteworthy
Bayes Factor
µB
Ct ωt 4 5
0.1
0.1 (29, 39, 87.050), 0.013 (31, 43, 100), 0.130
0.01 (49.975, 61, 87), 0.004 (44, 56.5, 82.025), 0.003
0.001 (64, 75, 95), 0.012 (57, 69, 88.025), 0.007
0.1
0.001 (29, 38, 76), 0.011 (31, 42, 100), 0.111
0.01 (50, 61, 82), 0.001 (45, 56, 77), 0.000
0.001 (87, 95, 100), 0.228 (80, 89, 100), 0.049
0.000001
0.1 (29, 38, 69.025), 0.006 (32, 42, 100), 0.104
0.01 (50, 61, 79.025), 0.001 (45, 55, 74), 0.001
0.001 (86.975, 96, 100), 0.281 (80, 89, 100), 0.060
more likely to have switched to the favorable treatment.
However, when ωt = 0.01 the median switch occurs at
72 (95% credible interval 59, 95.025) with a indecisive
Bayes Factor 0.014, indicating at N = 100 the switch to
the favorable treatment had not yet occurred. Finally, when
ωt = 0.001, the median switch occurs at 100 (95% credible
interval 99, 100) with a indecisive Bayes Factor 0.973, also
indicating at N = 100 the switch to the favorable treatment
had not yet occurred.
Lastly, using µB = 5 and ωt = 0.1 and ctB = 0.000001
the median switch occurs at 42 (95% credible interval 32,
100) with a indecisive Bayes Factor 0.104, indicating at
N = 100 the switch to the favorable treatment had not
yet occurred. However, when ωt = 0.01 the median switch
occurs at 55 (95% credible interval 44, 74) with a decisive
Bayes factor value 0.001 indicating this was 100 times
more likely to have switched to the favorable treatment.
Lastly, when ωt = 0.001 median switching value was 89
(95% credible interval 80, 100) with an indecisive Bayes
Factor value of 0.060, suggesting the switch to the favorable
treatment had not occurred at N = 100.
A careful examination of the remaining combinations
indicates that for µB = 1, 2, and 3 the only decisive Bayes
Factors ωt = 0.1, although the Bayes Factor does appear
to diminish in these cases when ωt = 0.01, yet it remains
indecisive. Likewise, at ωt = 0.001, the Bayes Factors are
highly indecisive. However, when analyzing µB = 4 the
Bayes Factors for ωt = 0.1 and 0.001 are decisive, while
that for ωt = 0.001 is indecisive. Interestingly, µB = 4 the
scenario for ωt = 0.001 is the only decisive Bayes Factor.
The behavior of these suggests if one wishes to investigate
the impact of a smaller mean and seek definitive results, it is
best to have lower certainty about the between time behavior
and use ωt = 0.1, however, for the larger means a bit more
certainty about between time variance ωt = 0.01 should be
used to detect a decisive difference.
Conclusion
Modern computational power has aided researchers by
decreasing the amount of time necessary to run large
simulations or large computationally difficult problems
which may arise from when using Bayesian methods.
Studies such as Bayesian adaptive designs in clinical trial
benefit from this increased computational power through
a decreased completion time, yet some Bayesian adaptive
designs remain time consuming. The current application
of the DLM to random allocation models illustrates its
benefit through both greatly reduced allocation time and
in decreased allocation size necessary to determine the
most appropriate treatment. Likewise the corresponding
sensitivity analysis illustrates the differing model behaviors
and allocation proportions which one may expect to see
when using the DLM to allocate patients to treatments.
Finally the power analysis conducted provides users the
ability to determine the proportion of available patient
budget they may wish to use to determine appropriate
stopping criterion. This should greatly reduce the number of
ineffective treatment allocations and begin allowing the most
effective treatment to be applied in a more timely manner
through a smaller patient budget size. However, the current
application focuses only on random allocation models with
no covariates therefore, the impact of a covariate such
as gender or smoker was not included in this article and
is something which will be addressed in a future article.
Likewise, the possibility of a multi arm study is something
which could be addressed in future work to determine if
a particular treatment allocation can be removed from the
study entirely. Additional future works may also include
examining the Bayes factor stopping criterion from a
survival analysis standpoint.
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